12 Health Care Stocks Moving In Monday’s Intraday Session
Gainers Atreca (NASDAQ:BCEL) stock rose 52.7% to $0.36 during Monday’s regular session. The market value of their outstanding…
12 Health Care Stocks Moving In Friday’s Intraday Session
Gainers Akso Health Group (NASDAQ:AHG) shares increased by 29.2% to $1.15 during Friday’s regular session. The market value…
Earnings Scheduled For November 13, 2023
Companies Reporting Before The Bell
• Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter.
• Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.
Earnings Preview For Y-mAbs Therapeutics
Y-mAbs Therapeutics (NASDAQ:YMAB) is set to give its latest quarterly earnings report on Monday, 2023-11-13. Here’s what investors…
Y-mAbs Names Michael Rossi As President And Chief Executive Officer And Director
Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic
Y-mAbs Announces Publication Of Naxitamab-Based Chemoimmunotherapy In Patients With Chemoresistant High-risk Neuroblastoma In The Journal Cancers
Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic
4 Analysts Have This to Say About Y-mAbs Therapeutics
Y-mAbs Therapeutics (NASDAQ:YMAB) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Earnings Scheduled For August 10, 2023
Companies Reporting Before The Bell
• IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
Analyst Expectations for Y-mAbs Therapeutics’s Future
Y-mAbs Therapeutics (NASDAQ:YMAB) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Where Y-mAbs Therapeutics Stands With Analysts
Over the past 3 months, 7 analysts have published their opinion on Y-mAbs Therapeutics (NASDAQ:YMAB) stock. These analysts…